Am J Cardiol. 2004 Jan 15;93(2):154-8.

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators.

Source

University of California, San Francisco School of Medicine, San Francisco, California 94110, USA. dwaters@medsfgh.ucsf.edu

Abstract

The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or 80 mg. During the double-blind period, low-density lipoprotein (LDL) cholesterol levels are expected to reach approximate mean values of 100 mg/dl (2.6 mmol/L) for the low-dose atorvastatin group and 75 mg/dl (1.9 mmol/L) for the high-dose group. Randomized patients are expected to be followed for an average of 5 years. The primary end point is the time to occurrence of a major cardiovascular event, defined as coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. The large patient numbers in the TNT study and long follow-up should ensure that there is adequate power to definitively determine if reducing LDL cholesterol levels to approximately 75 mg/dl (1.9 mmol/L) can provide additional clinical benefit.

PMID:: 14715339; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Molecular Biology Databases

Supplemental Content

Related citations

Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). [Am J Cardiol. 2007]
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H, Treating to New Targets (TNT) Steering Committee and Investigators. Am J Cardiol. 2007 Sep 1; 100(5):747-52. Epub 2007 Jun 14.
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. [Lancet. 2006]
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, et al. Lancet. 2006 Sep 9; 368(9539):919-28.
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. [Ann Intern Med. 2007]
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.
Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK, Treating to New Targets Study Steering Committee and Investigators. Ann Intern Med. 2007 Jul 3; 147(1):1-9.
Review ["Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease]. [Rev Med Liege. 2005]
Review ["Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease].
Scheen AJ. Rev Med Liege. 2005 Apr; 60(4):264-7.
Review Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients. [Can J Cardiol. 2006]
Review Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Fitchett DH, Leiter LA, Goodman SG, Langer A. Can J Cardiol. 2006 Aug; 22(10):835-9.

See reviews... See all...

Cited by 6 PubMed Central articles

Rosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients. [Tex Heart Inst J. 2011]
Rosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients.
Cevik C, Nugent K, Meyerrose G, Otahbachi M, Izgi C, Lyte M, Fish RD. Tex Heart Inst J. 2011; 38(3):229-33.
Review Reducing morbidity and mortality in high risk patients with statins. [Vasc Health Risk Manag. 2009]
Review Reducing morbidity and mortality in high risk patients with statins.
Singh V, Deedwania P. Vasc Health Risk Manag. 2009; 5(2):495-507. Epub 2009 Jun 7.
Review PROVE-IT proved it: lower is better--pro. [Can J Cardiol. 2006]
Review PROVE-IT proved it: lower is better--pro.
Leiter LA. Can J Cardiol. 2006 Feb; 22 Suppl B:91B-94B.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein chole...
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
Am J Cardiol. 2004 Jan 15 ;93(2):154-8.

PubMed
Serum 25-hydroxyvitamin D3 is related to fish intake and exercise in Korean adul...
Serum 25-hydroxyvitamin D3 is related to fish intake and exercise in Korean adult men.
Asia Pac J Clin Nutr. 2009 ;18(3):372-6.

PubMed
Review of efforts to decrease costly leg wound complications in the medicare pop...
Review of efforts to decrease costly leg wound complications in the medicare population following coronary revascularization.
Heart Surg Forum. 2003 ;6(4):258-63.

PubMed
Clinical trials that have influenced the treatment of venous thromboembolism: a ...
Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective.
Ann Intern Med. 2001 Mar 6 ;134(5):409-17.

PubMed
The control of dicumarol therapy and the quantitative determination of prothromb...
The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin.
Scand J Clin Lab Invest. 1951 ;3(3):201-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Supplemental Content

Related citations

Cited by 6 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information